Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;177(10):1237-1240.
doi: 10.1016/j.neurol.2021.05.001. Epub 2021 Jun 16.

Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection

K Bigaut  1 , L Kremer  2 , M Fleury  3 , L Lanotte  2 , N Collongues  2 , J de Seze  2
Affiliations

Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection

K Bigaut et al. Rev Neurol (Paris). 2021 Dec.

Abstract

Objective: To analyze the humoral response after COVID-19 vaccination in patients with multiple sclerosis (MS) according to disease-modifying treatments (DMTs) and in comparison with the humoral response after SARS-CoV-2 infection.

Methods: We included 28 MS patients with serological results after COVID-19 vaccination (Pfizer-BioNTech or Moderna ARNm) and 61 MS patients with serological results after COVID-19 (COVID-19 group) among patients followed up at the MS Center of Strasbourg, France, between January and April 2021. The primary endpoint was the IgG index according to DMTs (anti-CD20 mAb, sphingosine 1-phosphate receptor [S1PR] modulator and other treatments) and COVID-19 vaccine or COVID-19 groups.

Results: In the vaccinated MS patients, the median IgG index was lower in patients treated with anti-CD20 mAb and in patients treated with S1PR modulator compared to patients receiving other or no DMTs (4.80 [1.58-28.6], 16.5 [16.3-48.5], 1116 [434-1747] and 1272 [658-1886], respectively, P<0.001). Similar results were found for MS patients after COVID-19.

Conclusions: Patients with MS and treated with S1PR modulators or anti-CD20 mAb had a reduced humoral response after COVID-19 vaccine.

Keywords: Antibody; COVID-19; Humoral response; Multiple sclerosis; Vaccine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
IgG index according to the time between the last infusion of anti-CD20 mAb and the first dose of COVID-19 vaccine.
See this image and copyright information in PMC

References

    1. Sormani M.P., De Rossi N., Schiavetti I., Carmisciano L., Cordioli C., Moiola L., et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021 doi: 10.1002/ana.26028. - DOI - PMC - PubMed
    1. Louapre C., Collongues N., Stankoff B., Giannesini C., Papeix C., Bensa C., et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 doi: 10.1001/jamaneurol.2020.2581. - DOI - PMC - PubMed
    1. Achiron A., Mandel M., Dreyer-Alster S., Harari G., Magalashvili D., Sonis P., et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14 doi: 10.1177/17562864211012835. [17562864211012836] - DOI - PMC - PubMed
    1. Medistica. pvalue.io, a graphic user interface to the R statistical analysis software for scientific medical publications. Available on: https://www.pvalue.io 2020.
    1. Haute Autorité de Santé . 2021. La stratégie vaccinale et la liste des publics prioritaires. Ministère des Solidarités et de la Santé. [https://solidarites-sante.gouv.fr/grands-dossiers/vaccin-covid-19/public... (accessed April 26, 2021)]

Substances